• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Alnylam Pharmaceuticals

Alnylam Pharmaceuticals

  1. All
  2. 3rd Party
  1. Alnylam Reports Positive Interim Clinical Results for Fitusiran from Ongoing Phase 2 Open Label Extension Study in Patients with Hemophilia A or B without Inhibitors

    Alnylam Reports Positive Interim Clinical Results for Fitusiran from Ongoing Phase 2 Open Label Extension Study in Patients with Hemophilia A or B without Inhibitors

  2. Alnylam Reports Positive Interim Phase 1 Results for Fitusiran in Hemophilia A and B Patients with Inhibitors

    Alnylam Reports Positive Interim Phase 1 Results for Fitusiran in Hemophilia A and B Patients with Inhibitors

  3. Alnylam Reports Positive Initial Clinical Activity Results for Givosiran (ALN-AS1), an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias

    Alnylam Reports Positive Initial Clinical Activity Results for Givosiran (ALN-AS1), an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias

  4. US Biodefense Market Outlook 2022: Biodefense Market to Grow at a CAGR of 9% during the Forecasted Period of 2017-2022 - Research and Markets

    US Biodefense Market Outlook 2022: Biodefense Market to Grow at a CAGR of 9% during the Forecasted Period of 2017-2022 - Research and Markets

  5. Dodge & Cox Balanced Fund Isn't for Everyone

    This Gold-rated fund is not a safe choice, but it's a strong one for the right kind of investor.

  6. Investing in Hidden Assets

    Use this screen to find high-growth businesses that have big ideas to keep competitors at bay.

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.